Table 2 Patient-reported outcome scores and metabolite levels from T1 to T3 (N = 50)

QLQ-CIPN20 Sensory

2.22

(7.7)

9.15 (13.44)

7.41 (10.26)

6.88 (12.87)*

5.19 (10.23)*

QLQ-CIPN20 Motor

2.35 (8.17)

9.06 (18.24)

6.95 (11.26)

6.67 (14.22)*

4.61

(8.47)*

QLQ-CIPN20 Numbness and Tingling

3.17 (10.36)

14.12 (19.19)

13.17 (16.76)

10.88 (18.18)*

10.0 (16.92)*

NAD^+ a

1.34e^− 07 (9.22e^− 08)

1.28e^− 07 (1.02e^− 07)

1.2e^− 07 (1.23e^− 07)

1.08e^− 8 (1.49e^− 07)

-1.4e^− 08 (1.24e^− 07)

cADPR^b

6.65e^− 08 (6.96e^− 08)

6.10e^− 08 (5.17e^− 08)

6.23e^− 08 (7.34e^− 08)

-3.8e^− 09 (8.47e^− 08)

-4.2e^− 09 (7.68e^− 08)

ADPR^c

2.44e^− 07 (6.43e^− 07)

7.98e^− 08 (9.26e^− 08)

1.83e^− 07 (5.17e^− 07)

-1.64e^− 07

(-6.26e^− 07)

-1.93e^− 07 (9.95e^− 07)*

cADPR/NAD^+ d

0.63 (0.33)

0.79

(0.50)

0.71

(0.40)

0.13

(0.60)

0.08

(0.39)